INTRODUCTION: A big issue in world health is tuberculosis. Mycobacterium tuberculosis is the causative agent of extra-pulmonary tuberculosis (EPTB), which may manifest in a variety of ways and locations. Lymph nodes, CNS, pleural, abdominal, pericardial, urogenital, cutaneous, ophthalmic, and other sites are all potential sites of EPTB. An innovative approach, Truenat is a battery-operated, microdevice based real-time polymerase chain reaction (RT-PCR) for detecting mycobacterium tuberculosis (MTB) in clinical samples. A second chip may be used as a follow-up test to determine if Truenat MTB 'detected' samples have rifampicin resistance. The study's stated goals are to(1) investigate the current state of the art in EPTB diagnostic technology and(2) assess the specificity and sensitivity of these technologies. MATERIALS AND METHODS: At IGIMS in Patna, Bihar, India, researchers conducted a crosssectional study over the course of fifteen months. A total of 254 clinical samples from areas other than the lungs were examined. Inclusion Criteria: The trial included all patients with presumed EPTB who were at least one year old, had a prior history of anti-tubercular therapy (ATT), and whose treatment had failed during their most recent session of treatment. Exclusion Criteria: Participants who were on ATT or had pulmonary TB were not included in the research. Ziehl-Neelsen (ZN) staining was used for smear microscopy, Mycobacterium growth indicator tube (MGIT) culture, and Truenat PCR for Mycobacterium tuberculosis (MTB). The data was presented using summary statistics with a 95% Confidence Interval (CI), and comparisons were conducted between the tests. RESULT: A total of 254 samples were collected from areas beyond the lungs. Truenat found 26 cases of tuberculosis out of 254. CONCLUSION: For the diagnosis of EPTB in areas with limited resources, the Truenat MTB test provides an efficient and quick molecular diagnostic tool.